A Albani1, F Ferraù2, A Ciresi3, R Pivonello4, C Scaroni5, D Iacuaniello4, M Zilio5, V Guarnotta3, A Alibrandi6, E Messina7, M Boscaro5, C Giordano3, A Colao4, S Cannavo8,7. 1. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. 2. Department of Human Pathology of Adulthood and Childhood 'G. Barresi', University of Messina, Messina, Italy. francesco.ferrau1@gmail.com. 3. Section of Endocrinology, Diabetology and Metabolism, DIBIMIS, University of Palermo, Palermo, Italy. 4. Department of Clinical Medicine and Surgery, Endocrinology Unit, University of Naples Federico II, Naples, Italy. 5. Department of Medicine (DIMED), Endocrinology Unit, University-Hospital of Padua, Padova, Italy. 6. Department of Economics, University of Messina, Messina, Italy. 7. Unit of Endocrinology, University Hospital 'G. Martino', Messina, Italy. 8. Department of Human Pathology of Adulthood and Childhood 'G. Barresi', University of Messina, Messina, Italy.
Abstract
PURPOSE: Patients with Cushing's disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. METHODS: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthropometric, clinical, and biochemical parameters and calculated VAI, ATD severity, Framingham, and atherosclerotic cardiovascular disease (ASCVD) risk scores, before and after 6 and 12 months of treatment with pasireotide (1200-1800 mcg/daily). RESULTS: Before starting pasireotide treatment, ATD was present in 7/16 patients (mild in 2/16, moderate in 3/16, and severe 2/16). After 12 months of treatment: (i) 24h-urinary free cortisol levels (p = 0.003), BMI (p < 0.001), waist circumference (p = 0.001), LDL-cholesterol (p = 0.033), total-cholesterol (p = 0.032), triglycerides (p = 0.030), VAI (p = 0.015), and ATD severity (p = 0.026) were significantly decreased as compared to baseline; (ii) ATD was present in only 1/16 patients; (iii) prevalence of diabetes mellitus (p = 0.015) and HbA1c levels (p = 0.001) were significantly increased as compared to baseline; (iv) Framingham and ASCVD risk scores were not significantly different from pre-treatment values. CONCLUSIONS: Twelve-month pasireotide treatment significantly reduces VAI and ATD in CD patients. These positive effects on cardiometabolic risk occur despite no change in Framingham and ASCVD risk scores and the increase in the prevalence of diabetes mellitus.
PURPOSE:Patients with Cushing's disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CDpatients. METHODS: This is a multicentre, prospective, and observational study. Sixteen CDpatients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthropometric, clinical, and biochemical parameters and calculated VAI, ATD severity, Framingham, and atherosclerotic cardiovascular disease (ASCVD) risk scores, before and after 6 and 12 months of treatment with pasireotide (1200-1800 mcg/daily). RESULTS: Before starting pasireotide treatment, ATD was present in 7/16 patients (mild in 2/16, moderate in 3/16, and severe 2/16). After 12 months of treatment: (i) 24h-urinary free cortisol levels (p = 0.003), BMI (p < 0.001), waist circumference (p = 0.001), LDL-cholesterol (p = 0.033), total-cholesterol (p = 0.032), triglycerides (p = 0.030), VAI (p = 0.015), and ATD severity (p = 0.026) were significantly decreased as compared to baseline; (ii) ATD was present in only 1/16 patients; (iii) prevalence of diabetes mellitus (p = 0.015) and HbA1c levels (p = 0.001) were significantly increased as compared to baseline; (iv) Framingham and ASCVD risk scores were not significantly different from pre-treatment values. CONCLUSIONS: Twelve-month pasireotide treatment significantly reduces VAI and ATD in CDpatients. These positive effects on cardiometabolic risk occur despite no change in Framingham and ASCVD risk scores and the increase in the prevalence of diabetes mellitus.
Entities:
Keywords:
Cardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index
Authors: G Ntali; A Asimakopoulou; T Siamatras; J Komninos; D Vassiliadi; M Tzanela; S Tsagarakis; A B Grossman; J A H Wass; N Karavitaki Journal: Eur J Endocrinol Date: 2013-10-08 Impact factor: 6.664
Authors: O M Dekkers; N R Biermasz; A M Pereira; F Roelfsema; M O van Aken; J H C Voormolen; J A Romijn Journal: J Clin Endocrinol Metab Date: 2007-01-02 Impact factor: 5.958
Authors: Annamaria Colao; Stephan Petersenn; John Newell-Price; James W Findling; Feng Gu; Mario Maldonado; Ulrike Schoenherr; David Mills; Luiz Roberto Salgado; Beverly M K Biller Journal: N Engl J Med Date: 2012-03-08 Impact factor: 91.245
Authors: Rosario Pivonello; Stephan Petersenn; John Newell-Price; James W Findling; Feng Gu; Mario Maldonado; Andrew Trovato; Gareth Hughes; Luiz R Salgado; André Lacroix; Jochen Schopohl; Beverly M K Biller Journal: Clin Endocrinol (Oxf) Date: 2014-03-27 Impact factor: 3.478
Authors: Maria Fleseriu; Stephan Petersenn; Beverly M K Biller; Pinar Kadioglu; Christophe De Block; Guy T'Sjoen; Marie-Christine Vantyghem; Libuse Tauchmanova; Judi Wojna; Michael Roughton; André Lacroix; John Newell-Price Journal: Clin Endocrinol (Oxf) Date: 2019-10-01 Impact factor: 3.478
Authors: Rosario Pivonello; Atanaska Elenkova; Maria Fleseriu; Richard A Feelders; Przemyslaw Witek; Yona Greenman; Eliza B Geer; Paola Perotti; Leonard Saiegh; Fredric Cohen; Giorgio Arnaldi Journal: Front Endocrinol (Lausanne) Date: 2021-04-07 Impact factor: 5.555
Authors: David Stevens; Deirdre A Lane; Stephanie L Harrison; Gregory Y H Lip; Ruwanthi Kolamunnage-Dona Journal: BMC Med Res Methodol Date: 2021-12-18 Impact factor: 4.615